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Abstract
Background: Most randomised clinical trials typically exclude a significant proportion of asthma patients, including
those at higher risk of adverse events, with comorbidities, obesity, poor inhaler technique and adherence, or
smokers. However, these patients might differentially benefit from extrafine-particle inhaled corticosteroids (ICS).
This matched cohort, database study, compared the effectiveness of extrafine-particle with fine-particle ICS in a real-
life population initiating ICS therapy in the Netherlands.
Methods: Data were from the Pharmo Database Network, comprising pharmacy and hospital discharge records,
representative of 20 % of the Dutch population. The study population included patients aged 12 − 60, with a
General Practice-recorded diagnosis for asthma (International Classification of Primary Care code R96), when
available, ≥2 prescriptions for asthma therapy at any time in their recorded history, and receiving first prescription
of ICS therapy as either extrafine-particle (ciclesonide or hydrofluoroalkane beclomethasone dipropionate [BDP]) or
fine-particle ICS (fluticasone propionate or non-extrafine-particle-BDP). Patients were matched (1:1) on relevant
demographic and clinical characteristics over 1-year baseline. Primary outcomes were severe exacerbation rates, risk
domain asthma control and overall asthma control during the year following first ICS prescription. Secondary
outcomes, treatment stability and being prescribed higher versus lower category of short-acting β2 agonists (SABA)
dose, were compared over a 1-year outcome period using conditional logistic regression models.
Results: Following matching, 1399 patients were selected in each treatment cohort (median age: 43 years; males:
34 %). Median (interquartile range) initial ICS doses (fluticasone-equivalents in μg) were 160 (160 − 320) for
extrafine-particle versus 500 (250 − 500) for fine-particle ICS (p < 0.001). Following adjustment for residual
confounders, matched patients prescribed extrafine-particle ICS had significantly lower rates of exacerbations
(adjusted rate ratio [95 % CI], 0.59 [0.47–0.73]), and significantly higher odds of achieving asthma control and
treatment stability in the year following initiation than those prescribed fine-particle ICS, and this occurred at lower
prescribed doses. Patients prescribed extrafine-particle ICS had lower odds of being prescribed higher doses of
SABA (0.50 [0.44–0.57]).
Conclusion: In this historical, matched study, extrafine-particle ICS was associated with better odds of asthma
control than fine-particle ICS in patients prescribed their first ICS therapy in the Netherlands. Of importance, this
was reached at significantly lower prescribed dose.
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Background
Traditional randomized controlled trials (RCT) aim to
establish a clear cause-and-effect relationship between
an intervention and an outcome. Although asthma RCTs
have high internal validity, a problem is that they typic-
ally represent fewer than 5 % of patients with a current
diagnosis of asthma [1, 2]. Patients at high risk of ad-
verse events, with comorbid conditions such as obesity,
rhinitis or smoking, or those with poor inhaler technique
and adherence, are typically excluded. Real-life research
can help balance the limitations of a RCT design [1].
Using real-life medical information recorded in primary
care databases allows assessment of long-term outcomes
in broader asthma populations cared for under usual
conditions. These populations also include patients with
unstable asthma often excluded from RCTs, but rou-
tinely seen by clinicians in primary care settings [3].
Traditional inhaler devices for controlling asthma
symptoms produce fine particles with a mass median
aerodynamic diameter (MMAD) of 2–4 μm; however,
some newer pressurized metered dose inhalers (pMDI)
using hydrofluoroalkane propellant generate an aerosol
of smaller, extrafine-particles with an MMAD <2 μm
[4, 5]. RCTs 8–12 weeks in duration have reported that
extrafine-particle ICS is equally effective as fine-particle
ICS in controlling asthma symptoms [6, 7]. Some pa-
tients typically excluded in these studies (see above)
might differentially benefit from extrafine-particle ICS
[4]. For these reasons, real-life database comparative ef-
fectiveness studies may usefully complement traditional
RCTs to evaluate whether different properties of
extrafine-particle and fine-particle ICS result in differ-
ent effects in broader clinical populations.
Relevant real-life database studies in the UK and US
show matched asthma patients prescribed extrafine-
particle hydrofluoroalkane beclomethasone dipropionate
(EF-HFA-BDP) for the first time had equivalent or better
odds of achieving asthma control over 1 year than pa-
tients initiating fluticasone, despite being prescribed
lower doses [8–10]. In contrast to findings from some
RCTs [6, 7], these studies suggest that extrafine-particle
ICS offers further clinical benefits in asthma control
compared with fine-particle ICS therapy in real-life pop-
ulations. To determine whether this finding can be
generalized in other settings with different healthcare
systems and possibly different prescribing habits, this
real-life database study compared the effectiveness of
initiating ICS therapy in patients with asthma in the
Netherlands prescribed extrafine-particle ciclesonide or
EF-HFA-BDP (Qvar®) versus fine-particle ICS fluticasone
propionate or non-extrafine-particle-beclomethasone di-
propionate (Non-EF-BDP). In line with previous real-life
research [8–10], it was hypothesized that EF-ICS may be
at least as effective as fine-particle ICS therapy.
Methods
Study design and data source
This was a matched cohort, database study, consisting of
a baseline and outcome period. The baseline period
served for patient characterization and confounder def-
inition and was 1 year before the initiation date of ICS
therapy. The outcome period was 1 year following the
initiation date for evaluating the effectiveness of ICS
therapy. The initiation date was the date when patients
received their first prescription of extrafine-particle ICS
(either ciclesonide or EF-HFA-BDP), or fine-particle ICS
(either fluticasone or Non-EF-BDP). The study period
was from January 1998 to December 2012.
An independent steering committee was involved in a
priori development of study design, review of analyses and
interpretation of results [11]. The study was registered
with the European Network of Centres for Pharmacoepi-
demiology and Pharmacovigilance (ENCePP, study no.
8391), and conducted in accordance with the ENCePP
Code of Conduct. The study design is summarized in
Additional file 1: Figure S1.
Anonymous data to inform the study objectives were
obtained from the Pharmo Database Network pro-
vided by the Pharmo Institute for Drugs Outcome
Research (Utrecht, the Netherlands). The Pharmo
Database Network comprises, among other databases,
linked Outpatient Pharmacy, General Practice (GP),
Hospitalization and Clinical Laboratory Register data-
bases, and accounts for almost 3 million patients’,
representative of 20 % of the Dutch population. The
Outpatient Pharmacy database includes the dispensing
records of more than 200 community pharmacies and
is linked to hospital discharge records. Data from the
Pharmo Institute were provided in accordance with
Dutch privacy laws.
Study population
The study population included adult patients aged 12–60
years with evidence of asthma, defined as ≥2 prescriptions
for asthma therapy at any time in their recorded history, a
General Practice-recorded diagnosis for asthma (Inter-
national Classification of Primary Care [ICPC] code R96),
when available, and receiving continuous ICS therapy fol-
lowing the initiation date, defined as ≥2 ICS prescriptions
during the outcome period in addition to the first prescrip-
tion. Patients were excluded from the study if, at any time,
they had been diagnosed with any chronic respiratory dis-
eases other than asthma. Patients prescribed long-acting
muscarinic antagonists at baseline were not excluded.
Outcomes
The rate of severe asthma exacerbations in the year fol-
lowing ICS therapy initiation, one of three co-primary
outcomes, was defined based on the American Thoracic
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Society/European Respiratory Society (ATS/ERS) Task
Force definition to include asthma-related hospital ad-
missions or prescription for acute courses of oral corti-
costeroids. Asthma-related admissions were defined as
any hospital entry for asthma or any lower respiratory
reason (including lower respiratory tract infections).
Acute oral corticosteroid use associated with asthma ex-
acerbation treatment was defined as all courses that
were not maintenance therapy, and/or all courses where
dosing instructions suggested exacerbation treatment.
Emergency department data were not included in the
exacerbation definition as these data were not available
in the database. Two further co-primary outcomes
included risk-domain asthma control, defined as the ab-
sence of asthma-related hospital admissions and pre-
scription for acute courses of oral corticosteroids; and
overall asthma control, defined as achieved risk-domain
asthma control and average daily dose of ≤200 μg salbu-
tamol or ≤500 μg terbutaline.
Secondary outcomes were (1) treatment stability during
the outcome period, defined as achieving risk-domain
asthma control and no change in therapy; and (2) average
daily dose of short-acting β2 agonists (SABA), defined as
number of inhalers  Doses per inhaler365  strength; where
strength is inhaler dose (μg). Change in therapy was de-
fined as an ICS prescribed dose increase of ≥50 % or
addition of new asthma therapy, including leukotriene re-
ceptor antagonists (LTRA), theophylline, or long-acting β-
agonists (LABA).
Finally, two exploratory outcomes were (1) preva-
lence of oral candidiasis, based on the number and
percentage of patients who either received a diagnosis
of oral candidiasis in their hospital records, or the
number and percentage of topical oral prescriptions
for antifungals; and (2) hospitalization rate, defined as
the number of any recorded hospital entry for asthma
and/or any (asthma-related) lower respiratory reason
in the year following the initiation date. All outcomes
have been used in prior studies by the research group
and have been described previously [8–10].
Statistical analysis
The database extraction and statistical analysis plan
were written before any analyses were conducted [12].
All analysis was carried out using IBM SPSS Statistics
version 22, Microsoft Office EXCEL 2007, and SAS
version 9.3. Complete details on statistical analysis
methods are in the Additional file 1: Figure S1.
Patients were exact-matched (1:1) based on key base-
line demographic and clinical characteristics to ensure
comparison of similar patients and to reduce potential
confounders [13]. Matching criteria were informed
from baseline differences between treatment cohorts as
evidenced by exploratory analysis (t-test/chi square test,
p < 0.05), from expert clinical advice, and from previous
research experience, and included the following: sex,
age, exact year of ICS therapy initiation, severe exacer-
bations, LABA and LTRA prescriptions, and SABA
daily dose. Patients were matched sequentially on each
of the selected matching criteria. Patients who did not
match were excluded.
The rate of severe exacerbations in the outcome period
was compared between matched treatment cohorts using a
conditional Poisson regression model. The odds of achiev-
ing risk-domain asthma control and overall asthma control,
and changing asthma therapy, were compared between
matched treatment cohorts using a conditional binary logis-
tic regression model. Ordinal conditional logistic regression
modeling was used to analyze prescriptions of higher doses
of SABA (categorized doses). The models used empirical
standard errors (for more conservative confidence interval
[CI] estimations) and adjustments were made for any re-
sidual non-collinear baseline confounders (Pearson and
Spearman correlation coefficients, r > 0.3) and for those
variables predictive of the results through full multivariable
analysis (multivariable model, p ≤ 0.05). The results are
expressed as adjusted rate ratios and odds ratios and 95 %
confidence intervals. Number of prescriptions of antifungal
medications to treat oral candidiasis, prevalence of hospital-
izations, and initial ICS doses were compared between the
two matched cohorts through conditional logistic regres-
sion (p < 0.05).
Results
Patient characteristics and demographics
Following 1:1 matching, 1399 patients were selected in
each of the extrafine-particle ICS and fine-particle ICS
cohorts (Fig. 1).
Within the extrafine-particle cohort, 712 patients (51 %)
were prescribed ciclesonide, 687 (49 %) EF-HFA-BDP. Me-
dian (interquartile range [IQR]) age for patients in each of
the matched cohorts was 43 years. Median (IQR) ICS doses
(μg) were 160 (160–320) for the extrafine-particle cohort
versus 500 (250–500) for the fine-particle cohort (p < 0.001)
(fluticasone-equivalents) (Fig. 2).
The two study cohorts were similar for the study
asthma control measures and prescriptions for SABA
(Table 1). However, at baseline, patients in the extrafine-
particle cohort received more diagnoses for rhinitis and
gastro-oesophageal reflux disease, more prescriptions for
acute oral corticosteroids, topical corticosteroid therapy,
and had a higher prevalence of asthma-related hospital
admissions, than patients in the fine-particle cohort
(Table 1). For these specific variables, data were compar-
able within the extrafine-particle cohort for patients pre-
scribed ciclesonide and EF-HFA-BDP (Table 1).
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Outcomes
Patients who received extrafine-particle ICS had 40 %
lower rates of severe exacerbations in the year following
the initiation date than those receiving fine-particle ICS
therapy, following adjustment for residual confounders
(adjusted rate ratio [95 % CI], 0.59 [0.47–0.73]) (Table 2).
In addition, patients in the extrafine-particle cohort had
greater odds of achieving risk-domain asthma control,
overall asthma control, and treatment stability, and had
lower odds of being in a higher dose category of SABA
Fig. 1 Patient flow chart showing selection of patients in the Pharmo Database Network Patients in the two study cohorts were matched on
clinically and demographically significant characteristics. Pharmo: Pharmo Database Network provided by the Pharmo Institute for Drugs
Outcome Research (Utrecht, the Netherlands). ICS: inhaled corticosteroid; initiation date: the date when patients received their first prescription of
extrafine-particle ICS (ciclesonide or EF-HFA-BDP), or fine-particle ICS (fluticasone or Non-EF-BDP)
Fig. 2 Dose of inhaled corticosteroids prescribed on the initiation date*. Reported doses are the actual dose for extrafine-particle ICS (ciclesonide
or EF-HFA-BDP) and the fluticasone-equivalent dose for fine-particle ICS (fluticasone and Non-EF-BDP). * Initiation date: the date when patients
received their first prescription of extrafine-particle ICS (ciclesonide or EF-HFA-BDP), or fine-particle ICS (fluticasone or Non-EF-BDP)
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(adjusted rate ratio [95 % CI], 0.50 [0.44–0.57])
(Table 2).
During the outcome year, patients in the extrafine-
particle cohort received fewer prescriptions for other re-
spiratory drugs (oral corticosteroids, SABA and LABA)
compared with the fine-particle cohort, although more
patients in the extrafine-particle cohort were prescribed
LTRAs during the outcome period than the fine-particle
cohort (6 % and 3 % in extrafine-particle versus fine-
particle ICS cohorts, respectively; p = 0.001) (Table 2).
Prescriptions of medications for treating oral candidiasis
in the outcome period were not significantly different
between the two study cohorts. Although patients in the
extrafine-particle cohort had significantly higher asthma-
related hospital admissions in baseline (Table 1), in the
year following the date of first prescription of ICS ther-
apy, this difference was not evident (Table 2).
Discussion
In this real-life population-based study, matched patients
initiating extrafine-particle ICS had significantly lower rates
of severe exacerbations and significantly higher odds of
achieving asthma control and treatment stability than those
prescribed fine-particle ICS. Notably, the prescribed doses
of extrafine-particle ICS were lower than fine-particle ICS
at the initiation date (median dose, 160 vs. 500 μg per day,
fluticasone-equivalents). In addition, patients prescribed
extrafine-particle ICS showed lower odds of being
prescribed higher doses of short-acting β2 agonists. Out-
come data showed no significant differences between the
study cohorts for medications prescribed for treating oral
candidiasis, and for asthma-related hospital admissions.
These findings suggest a significant improvement in asthma
control for patients prescribed extrafine-particle ICS with
unstable asthma. Such patients would typically be excluded
from traditional RCTs.
Possible mechanisms to account for the superior effect-
iveness of extrafine-particle ICS observed in this study
include improved airway drug deposition and distribution,
including distally in the small airways, and improved in-
haler device tolerance. These are each discussed in turn
below.
Aerosol particle size now appears therapeutically im-
portant for controlling asthma symptoms [14]. Evidence
indicates that fine-particle ICS with a MMAD of <5 μm,
but ≥2 μm, show lower total lung distribution and de-
position than extrafine-particles with a MMAD <2 μm,
which can deposit more in the small airways [1, 2, 15].
More effective control of small airway inflammation
might contribute to improved asthma control [15].
Poor device technique by patients is a common problem
observed by clinicians. Asthma control worsens as the
number of mistakes in device technique increases [16].
The combination of fine-particle ICS with poor device
technique can lead to some of the ICS settling in the oro-
pharynx, resulting in side-effects such as oropharyngeal
Fig. 3 Adjusted rate and odds ratios (95 % CI) for co-primary and secondary outcomes. ICS: inhaled corticosteroid; SABA, short-acting β2-agonist.
*Adjusted for baseline exacerbations (ATS/ERS Definition, categorized), evidence of GERD and baseline asthma prescriptions (categorized); †Ad-
justed for baseline Risk Domain Asthma Control, evidence of GERD and asthma diagnosis; ‡Adjusted for evidence of rhinitis, evidence of GERD
and baseline Risk Domain Asthma Control; §Adjusted for baseline SABA daily dose
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Table 1 Baseline demographic and clinical characteristics for 1:1 matched patients
Baseline Characteristic Extrafine-particle
ICSa (n = 1399)
Fine-particle ICSb
(n = 1399)
p-value
Sex, male, n (%)c 471 (34) 471 (34) N/A
Age, median (IQR)c 43 (32–53) 43 (32–52) 0.091
Year of initiation date, median (IQR)c 2008 (2006–2009) 2008 (2006–2009) N/A
ICS dose prescribed on initiation date, n (%)
<200μg/d, n (%) 866 (62) 218 (16) <0.001
201–400μg/d, n (%) 477 (34) 301 (22)
401–800μg/d, n (%) 56 (4) 677 (48)
801μg/d, n (%) 0 (0) 203 (15)
ICS dose on initiation date, median (IQR) 160 (160–320) 500 (250–500) <0.001
Average ICS daily dose (μg/d, categorized EF-HFA-BDP/ciclesonide equivalent dosed)
0–200μg/d, n (%) 866 (62) 218 (16) <0.001
201–400μg/d, n (%) 477 (34) 301 (22)
401–800μg/d, n (%) 56 (4) 677 (48)
801μg/d+, n (%) 0 (0) 203 (15)
Recorded comorbidity, n (%)
Rhinitis diagnosis, n (%) 623 (45) 536 (38) <0.001
GERD diagnosis, n (%) 513 (37) 437 (31) 0.001
Paracetamol script, n (%) 28 (2) 47 (3) 0.020
NSAID script, n (%) 219 (16) 215 (15) 0.834
Topical corticosteroid treatment, n (%) 433 (31) 374 (27) 0.014
Oral candidiasis diagnosis, n (%) 14 (1) 11 (1) 0.533
Rhinitis diagnosis, n (%) Ciclesonide 18 (1) N/A N/A
EF-HFA-BDP 21 (1)
GERD diagnosis, n (%) Ciclesonide 0 (0) N/A N/A
EF-HFA-BDP 1 (1)
Topical corticosteroid treatment, n (%) Ciclesonide 207 (15) N/A N/A
EF-HFA-BDP 226 (16)
Respiratory Medications
Acute oral corticosteroid prescriptions, <1, n (%) 101 (7) 120 (9) 0.001
Acute oral corticosteroid prescriptions, <1, n (%) Ciclesonide 47 (3) N/A N/A
EF-HFA-BDP 54 (4)
SABA daily dose, n (%)c
0μg/d, n (%) 953 (68) 953 (68) N/A
200μg/d, n (%) 57 (4) 57 (4)
201μg/d, n (%) 40 (3) 40 (3)
SABA prescriptions, n (%)
0, n (%)c 953 (68) 953 (68) 0.251
1, n (%) 281 (20) 267 (19)
2+, n (%) 165 (12) 179 (13)
Prior therapy
LABA, n (%)c 21 (2) 21 (2) N/A
LTRA, n (%)c 1 (0) 1 (0) N/A
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candidiasis. However, lung deposition of EF-HFA-BDP
remains adequate even in patients with poor inhaler
device technique [1]. This may be due to pMDI design
incorporating hydrofluoroalkane propellant that produces
a softer, warmer and longer duration spray. This particular
method of delivery has proven more tolerant of poor in-
haler technique than some metered dose inhalers emitting
fine-particle ICS [1]. Tolerance to inhalation errors may in
turn promote improved adherence to therapy [14].
This study has several strengths. To ensure all poten-
tially relevant variables for characterizing patients were
included, and that the key outcomes of interest could be
evaluated, both the statistical analysis plan, study popu-
lation and outcomes were conceived prior to any ana-
lyses [11]. Imitating traditional RCT design, the study
included an initiation date marking therapy initiation.
The study inclusion and exclusion criteria were selected
to minimize potential confounding factors such as other
asthma therapies, and to identify patients from a large
clinical population receiving initial ICS therapy. Patient
matching was used to adjust for demographic and clin-
ical differences between the study cohorts. An advantage
of 1-year baseline and outcome periods is that this time-
period allows for natural seasonal changes in respiratory
disease, and for recording infrequent clinical events such
as exacerbations and asthma-related hospitalizations
[11]. The results confirm both the study hypothesis and
similar findings observed in real-life asthma control
studies with patients in the UK and US [8–10]. This
seems to suggest that the present findings can be extrap-
olated to healthcare systems and prescribing patterns in
different countries. Collectively, these studies provide
balance to findings reported in some RCTs that
extrafine-particle ICS is only equally effective as fine-
particle ICS in achieving asthma control [3, 4].
However, as with all real-life comparative database
studies, this study has its limitations as well. Limita-
tions could derive from using the Pharmo Database
Network, including disease misclassification biases
from the almost exclusive use of “asthma prescrip-
tions” to individuate patients with asthma, and the
impossibility to adjust for all potential confounders,
such as potential confounding by severity for factors
indiscernible from patient records or patient-reported
outcomes. Asthma diagnosis data, defined as a
General Practice recorded diagnosis for asthma (ICPC
code R96), were available in the General Practice
database for only 12.2 % of the study population. In
addition, the results of this study only apply to
healthier patients who survive at least 1 year follow-
ing prescription date. Therefore, this study cannot ex-
clude potential survivor bias [11, 13, 17].
Although specific to respiratory disease, this study
could not accurately assess lung function, or symptom
control. However, short-acting β2 agonist prescriptions
were included in the study as a substitute for asthma
symptoms in the ‘overall asthma control’ measure, be-
cause short-acting β2 agonist use reflects symptom con-
trol [18]. The control cutoff point of a mean short-
acting β2 agonist use of ≥2 puffs per day corresponds to
the level 2 category (2 of 4, with 1 being the best con-
trolled) of the validated approach of Schatz et al. [18] for
short-acting β2 agonist canister dispensing to assess
asthma symptom control. During the study period,
1399/2981 (47 %) eligible patients initiating extrafine-
particle ICS therapy were matched, and 1399/8200
(17 %) of those initiating fine-particle ICS were matched,
possibly indicating that patients in neither cohort were
representative of those who initiate extrafine-particle or
fine-particle ICS therapy in the Netherlands. Finally,
Table 1 Baseline demographic and clinical characteristics for 1:1 matched patients (Continued)
Asthma control
Risk-domain asthma control, n (%)c 1275 (91) 1275 (91) N/A
Overall asthma control, n (%)c 1241 (89) 1241 (89) N/A
Severe exacerbations, n (%)c
0 1275 (91) 1275 (91) N/A
1 109 (8) 109 (8)
2+ 15 (1) 15 (1)
Asthma-related hospital admissions, n (%) 23 (2) 4 (0) 0.001
Asthma-related hospital admissions, n (%) Ciclesonide 11 (1) N/A N/A
EF-HFA-BDP 12 (1)
GERD, gastro-oesophageal reflux disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; N/A: not applicable; SABA,
short-acting β2-agonist; initiation date: the date when patients received their first prescription of extrafine-particle ICS (ciclesonide or EF-HFA-BDP), or fine-particle
ICS (fluticasone or Non-EF-BDP)
aExtrafine-particle ICS: ciclesonide; hydrofluoroalkane beclomethasone dipropionate (EF-HFA-BDP)
bFine-particle ICS: non-extrafine-particle beclomethasone dipropionate (Non-EF-BDP); fluticasone propionate
cMatching variable
dAverage ICS daily dose calculated as [(number of inhalers * doses per inhaler / 365) * µg strength]
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Table 2 Outcome measures for matched groups 1 year following date of first ICS prescription
Outcome Extrafine-particle ICSa
(n = 1399)
Fine-particle ICSb
(n = 1399)
p-value
Asthma control
Risk-domain asthma control, n (%) 1236 (88) 1129 (81) <0.001
Overall asthma control, n (%) 1091 (78) 934 (67) <0.001
Severe exacerbations, n (%)
0, n (%) 1236 (88) 1129 (81) <0.001
1, n (%) 108 (8) 184 (13)
2+, n (%) 55 (4) 86 (6)
Treatment stability, n (%) 809 (58) 560 (40) <0.001
Prescribed average daily dose of SABA, μg/d, n (%)
0 μg/d, n (%) 686 (49) 461 (33) <0.001
1–100 μg/d, n (%) 326 (23) 343 (25)
101 μg/d+, n (%) 387 (28) 595 (43)
1+ prescriptions of antifungal for candidiasis, n (%) 48 (3) 45 (3) 0.753
1+ asthma-related hospital admissions, n (%) 19 (1) 16 (1) 0.613
Respiratory medications in outcome period
Courses of acute oral corticosteroids, n (%)
0, n (%) 1246 (89) 1135 (81) <0.001
1, n (%) 102 (7) 182 (13)
2+, n (%) 51 (5) 82 (6)
SABA prescriptions, n (%)
0, n (%) 686 (49) 461 (33) <0.001
1, n (%) 245 (18) 235 (17)
2, n (%) 180 (13) 218 (16)
3+, n (%) 288 (21) 485 (35)
ICS prescriptions (including initial prescription)
2, n (%) 0 (0) 0 (0) 0.022
3, n (%) 462 (33) 520 (37)
4+, n (%) 937 (67) 879 (63)
Average ICS daily dose (μg/d, fluticasone-equivalentsc)
0–150 μg/d, n (%) 460 (33) 263 (19) <0.001
151–250 μg/d, n (%) 484 (35) 416 (30)
251–450 μg/d, n (%) 358 (26) 401 (29)
451 μg/d+, n (%) 97 (7) 319 (23)
Average ICS daily dose (μg/d, EF-HFA-BDP/
ciclesonide equivalent dosed), median (IQR)
185 (132–290) 272 (178–410) <0.001
Average ICS daily dose (μg/d, EF-HFA-BDP/
ciclesonide equivalent dosed)
0–150 μg/d, n (%) 460 (33) 263 (19) <0.001
151–250 μg/d, n (%) 484 (35) 416 (30)
251–450 μg/d, n (%) 358 (26) 401 (29)
451 μg/d+, n (%) 97 (7) 319 (23)
LABA prescriptions in outcome period 770 (55) 875 (63) <0.001
LTRA prescriptions in outcome period 83 (6) 47 (3) 0.001
GERD gastro-oesophageal reflux disease, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LTRA leukotriene receptor antagonist, N/A not applicable, SABA
short-acting β2-agonist
a Extrafine-particle ICS: ciclesonide (Alvesco®); hydrofluoroalkane beclomethasone dipropionate (EF-HFA-BDP [Qvar®])
b Fine-particle ICS: non-extrafine-particle beclomethasone dipropionate (Non-EF-BDP); fluticasone propionate (FP)
c Fluticasone-equivalent dose for fine-particle ICS (FP and Non-EF-BDP) delivered via a pressurized metered dose inhaler
d EF-HFA-BDP/ciclesonide equivalent dose for extrafine-particle ICS delivered via a pressurized-metered dose inhaler
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although smoking status was not reported in the study
due to poor availability within the Pharmo Database
Network, possible COPD patients were included (e.g.,
patients prescribed long-acting muscarinic agents in
addition to ICS), but constituted only 1.8 % of the total
study population.
Conclusions
This study in a real-life population shows that extrafine-
particle ICS are associated with better asthma control
and better odds of therapy stability than fine-particle
ICS, at significantly lower prescribed doses, despite pa-
tients having otherwise similar baseline characteristics
after exact matching. These results for a Dutch popula-
tion confirm relevant real-life asthma studies conducted
in the UK and US, and seem generalizable to countries
with different healthcare systems and prescribing habits.
The findings also provide balance to findings reported in
some randomized asthma RCTs. The study applied reli-
able prescribing and medical information recorded in a
well-maintained database for a diverse clinical popula-
tion, a population including those at high risk of exacer-
bations, with comorbid rhinitis, smokers and non-
smokers. Although patients prescribed extrafine-particle
ICS showed signs of more severe asthma, they had bet-
ter asthma control at lower ICS doses than patients pre-
scribed fine-particle ICS. Additional comparative
effectiveness studies are required to better understand
the differential effects of extrafine-particle versus fine-
particle ICS in real-life asthma patients, especially re-
garding possible subgroup specificities.
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